About EGFR Exon 20

About EGFR Exon 20

RYBREVANT®(amivantamab-vmjw) is the only targeted antibody treatment approved specifically for mNSCLC with EGFR exon 20 insertion mutations after chemotherapy that contains platinum

Non–small cell lung cancer is the most common type of lung cancer

lung_cancer

Metastatic non–small cell lung cancer (mNSCLC) occurs when healthy cells in the lungs start to change or grow uncontrollably and become cancerous.

As these cells grow, they form tumors. When cells from the primary tumor travel through the body, they can develop new tumors in other places, causing the cancer to spread. That means that the lung cancer has metastasized, or become metastatic.

A biomarker is any molecule that can be measured in tissues, blood, or other bodily fluids. Biomarkers can show that your body is working normally or abnormally, or even show signs of disease.

By identifying mutations in certain cells associated with mNSCLC, biomarker testing can help you and your doctor get more details about the disease and find the right treatment option.

In mNSCLC, biomarker testing can help doctors create a more personalized treatment plan

treatment_plan

An EGFR exon 20 insertion mutation is a biomarker of certain mutated cancer cells

cancer_cells

A protein called an epidermal growth factor receptor (EGFR) is found on both normal and cancer cells and drives cells to survive and spread.

In mNSCLC, an EGFR gene with an exon 20 insertion mutation can cause cancer cells to lose control over their growth, allowing them to multiply and spread to other parts of the body. Exon 20 insertion mutations not only cause cancers to grow and spread but common treatments, such as some tyrosine kinase inhibitors (TKIs), may not work for these mutations.

A certain kind of biomarker test, next-generation sequencing (NGS), can most reliably detect EGFR exon 20 insertion mutations.

Biomarker testing with NGS will help you and your doctor understand your disease so you can get a treatment personalized for your specific type of mNSCLC.

EGFR, epidermal growth factor receptor; mNSCLC, metastatic non–small cell lung cancer; NGS, next-generation sequencing; TKI, tyrosine kinase inhibitor.

Ask your doctor about getting tested for biomarkers like EGFR exon 20 insertion mutations using an FDA-approved test

mutations

about_rybrevant

Ask your doctor if you’ve been screened for EGFR exon 20 insertion mutations

Learn about the only treatment of its kind designed to target mNSCLC with EGFR exon 20 insertion mutations.

About RYBREVANT®

Register Updates

Register for Updates

Sign up to receive the latest news and information about RYBREVANT®

Register here